TEST ID CLFA Cryptococcus Antigen Screen with Titer, Spinal Fluid
Reporting Name
Cryptococcus Ag Screen w/Titer, CSFSpecimen Type
CSFSpecimen Required
Container/Tube: Sterile vial
Specimen Volume: 1 mL
Collection Instructions: Submit specimen from collection vial 2 (preferred), 3, or 4.
Specimen Minimum Volume
0.5 mL
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| CSF | Refrigerated (preferred) | 14 days |
| Frozen | 14 days |
Special Instructions
Testing Algorithm
If result is positive, Cryptococcus titer will be performed at an additional charge.
For more information see Meningitis/Encephalitis Panel Algorithm
Method Name
Lateral Flow Assay (LFA)
Reject Due To
| Gross hemolysis | Reject |
Reference Values
Negative
Reference values apply to all ages.
Day(s) Performed
Monday through Sunday
Reflex Tests
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| CLFAT | Cryptococcus Ag Titer, LFA, CSF | Yes | No |
Report Available
Same day/1 to 2 daysSpecimen Retention Time
14 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
CPT Code Information
87899-Cryptococcus screen
87899-Cryptococcus titer (if appropriate)
Forms
If not ordering electronically, complete, print, and send Infectious Disease Serology Test Request (T916) with the specimen.
Useful For
Aiding in the diagnosis of cryptococcosis
This test should not be performed as a screening procedure for the general population.
This test should not be used as a test of cure or to guide treatment decisions.
Clinical Information
Cryptococcosis is an invasive fungal infection caused by Cryptococcus neoformans or Cryptococcus gattii. C neoformans has been isolated from several sites in nature, particularly weathered pigeon droppings. C gattii was previously only associated with tropical and subtropical regions. More recently, however, this organism has been found to be endemic in British Columbia and the Pacific Northwestern United States and is associated with several different tree species.
Infection is usually acquired via the pulmonary route. Patients are often unaware of any exposure history. Approximately half of the patients with symptomatic disease have a predisposing immunosuppressive condition such as AIDS, steroid therapy, lymphoma, or sarcoidosis. Symptoms may include fever, headache, dizziness, ataxia, somnolence, and cough. While the majority of C neoformans infections occur in immunocompromised patient populations, C gattii has a higher predilection for infection of healthy individuals.(1,2)
In addition to the lungs, cryptococcal infections frequently involve the central nervous system (CNS), particularly in patients infected with HIV. Mortality among patients with CNS cryptococcosis may approach 25% despite antibiotic therapy. Untreated CNS cryptococcosis is invariably fatal. Disseminated disease may affect any organ system and usually occurs in immunosuppressed individuals.